Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Tap Tax Cuts and AMED Subsidies, not Price Premium, to Fuel Innovation: JMA Chief
The government should encourage innovation in the pharmaceutical industry through tax cuts and subsidies, instead of the current price-maintenance premium scheme, Japan Medical Association (JMA) President Yoshitake Yokokura stressed on April 6. The leader of Japan’s biggest doctors lobby made…
To read the full story
Related Article
- Annual Price Revisions of All Drugs Unacceptable: JMA Chief
December 1, 2016
- Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
November 28, 2016
ORGANIZATION
- FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
- JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
July 10, 2026
- Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
- Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
- Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…